Guillain-barré as an autoimmune disease

International Archives of Allergy and Immunology

Volumn 109, Issue 4, 1996, Pages 318-326

  Shoenfeld, Yehuda ^a,b   George, Jacob ^a,b   Peter, James B ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Specialty Laboratories   (United States)

Author keywords

Allergic neuritis; Autoantibodies; Autoimmune diseases; Autoimmunity; Experimental; Guillain Barr syndrome

Indexed keywords

AUTOIMMUNITY; CELLULAR IMMUNITY; DEMYELINATION; GUILLAIN BARRE SYNDROME; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; COMPLEMENT ACTIVATION; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEURITIS; PASSIVE IMMUNIZATION; PLASMAPHERESIS; POLYRADICULONEUROPATHY; T LYMPHOCYTE;

AUTOANTIBODY; AUTOANTIGEN; CYTOKINE; IMMUNOGLOBULIN;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, BIOLOGICAL; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PLASMAPHERESIS; POLYRADICULONEUROPATHY; T-LYMPHOCYTES;

EID: 0029664740     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237258     Document Type: Article

References (151)

1. Shoenfeld, Y, Isenberg DA: The Mosaic of Autoimmunity: Multiple Factors Involved in Autoimmune Disease. Amsterdam. Elsevier. 1988. Pp 1580.
2. Shoenfeld, Y, Isenberg DA: The mosaic of autoimmunity. Immunol Today 1989; 10:123-126.
3. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW: Chronic thyroiditis and autoimmuni-zation. JAMA 1985:166:1439-1462.
4. Rose NR, Bona C: Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today 1993; 14:426-430.
5. Ropper AH: The Guillain-Barre syndrome. N Engl J Med 1992:326:1130-1136.
6. Asbury, AK: Diagnostic considerations in Guillain-Barre syndrome. Ann. Neurol. 1981;9:1-5.
7. Rostami AM: Pathogenesis of immune-mediated neuropathies. Pediatr Res I993:33:S90-S94.
8. Linington C. Brostoff SW: Peripheral nerve antigens: in Dyck PJ. Thomas PK. Griffin JW. Low PA. Poduslo J (eds): Peripheral neuropathy. Philadelphia, Saunders. 1993. vol 3. pp 404-417.
9. Cook SD, Dowling PC, Murray MR, Whitaker JN: Circulating demyelinating factors in acute idiopathic polyneuropathy. Arch Neurol 1971: 24:136-144.
10. Cruz M, Emerudh J, Olsson T, Hojeberg B, Link H: Occurrence and isotypes of antibodies against peripheral nerve myelin in serum from patients with peripheral neuropathy and healthy controls. J Neurol Neurosurg Psychiatry 1988; 51:820-825.
11. Nyland FI, Aarli JA: Guillain-Barre syndrome: Demonstration of antibodies peripheral tissue. Acta Neurol Scand 1978;58:35-43.
12. Ryberg B, Hindfelt B, Nilsson B, Olsson IE: Antineural antibodies in Guillain Bane syndrome and lymphocytic meningoradiculitis. Arch Neurol 1984:41: i 277-1281.
13. Vrethem M., Skogh T, Berlin G, Holmgren H. Emerudh J: Antibodies to peripheral nerve myelin antibody may occur without clinical neuropathy in healthy persons. J Neuroimmunol 1991:31:219-222.
14. Koski CL: Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. Ann Neurol 1990: 27(suppl):S44-S47.
15. Yu RK, Ariga T, Kohriyanta T, Kusunoki S, Macda Y, Miyatani N: Autoimmune mechanisms in peripheral neuropathies. Ann Neurol 1990; 27(suppl):S30-S38.
16. Hyas AA, Willison HJ, Quarles RH, Jungalwala KB, Comblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM: Serum antibodies to gangliosides in Guillain-Barrc syndrome. Ann Neutol 1988:23:440-447.
17. Peris Cuello X, Salgado Rcmigio A, Gomez Jimenez J, Peracaula Picart R: Guillain-Barré syndrome as initial manifestation of human immunodeficiency virus infection. Rev Clin Esp 1993:192:52.
18. Weller M, Stevens A, Sommer N, Wietholter H: Are CSF or serum gangliosidc antibodies related to peripheral nerve demyelination in neuro-borrcliosis. Guillain-Barrc syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy'.’ Eur Arch Psychiatry Clin Ncurosei 1992:242:122-126.
19. Ilyas AA. Mithen FA. Chen ZW. Cook SD: An-ti-GIgA antibodies in Guillain-Barre syndrome. J Neuroimmunol 1992:36:69-76.
20. Yuki N, Yoshino H, Sato S, Miyatake T: Acute axonal polyneuropathy associated with anti-GMI antibodies following Campylobacter enteritis. Neurology 1990:40:1900-1902.
21. Gregson NA, Koblar S, Hughes RAC: Antibodies to gangliosides in Guillain-Barre syndrome: Specificity and relationship to clinical features. Quart J Med 1993:86:111-117.
22. Simone H, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P: Serum and CSF anti-GMI antibodies in patients with Guillain-Barre syndrome and chronic inflammatory demyeli-nating polyneuropathy. J Neurol Sci 1993:114: 49-55.
23. M, antibodies in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1992:55:8-11.
24. Irie S, Saito T, Ogino M, Ito H, Kowa H: Antibodies to GM I gangliosidc in motor neuron disease in comparison with demyclinating neuropathy. Rinsho Shinkeigaku 1992:32:1075-1080.
25. Willison HJ, Vcitch J, Paterson G, Kennedy PGE: Miller Fisher syndrome is associated with serum antibodies with GQlb gangliosidc. J Neurol Neurosurg Psychiatry 1995:56:204-206.
26. Ilyas AA, Mithen FA, Dalakas MC, Wargo M, Chen ZW, Biclory L, Cook SD: Antibodies to sulfated glycolipids in Guillain-Barre syndrome. J Neurol Sci 1991; 105:108-117.
27. Koski CL, Chou DKH, Jungalwala FB: Anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral myelin and eross-reaet with Forssman antigen. J Clin Invest 1989;84:280-287.
28. Zweiman B, Rostami A, Lisak P, Moskovitz AR, Pleasure DF,: Immune reactions to P. protein in human inflammatory dcmyelinative neuropathies. Neurology 1983:33:234-237.
29. Koski CL, Jungalwala FB, Chou D: Anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral nerve myelin and cross-react with Forssman antigen. Ann Neurol 1988:24:122.
30. Quarles RH, Ilyas AA, Willison HJ: Antibodies to gangliosides and myelin proteins in Guillain-Barre Syndrome. Ann Neurol 1990;27(suppl): S48-S52.
31. Gilburd B, Stein M, Tomer Y, Tanne D, Abram-ski O, Chapman Y, Ahiron A, Blank M, Shoen-fekl Y: Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barre syndrome. Cross-reactive or pathogenic. Autoimmunity 1993;16:23-27.
32. van Doom PA, Brand A, Vermculen M: Antineuroblastoma cell line antibodies in inflammatory demyclinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin. Neurology 1988:38:1592-1595.
33. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RAC: Antibody response to P0 and P2 myelin proteins in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculopathy. J Neuroimmunol 1993:46:245-252.
34. Quarles RH, Ilyas AA, Willison HJ: Antibodies to ganglosidcs and myelin proteins in Guillain-Barre syndrome. Ann Neurol 1990:27(suppl): S48-S52.
35. Connolly AM, Pestronk A, Trotter JL, Feldman EL, Cornblath DR, Olney RK: Hightiter selective scrum anti-fltubulin antibodies in chronic inflammatory demyclinating polyneuropathy. Neurology 1993:43:557-562.
36. Latov N: Neuropathy and anti-GM I antibodies. Ann Neurol 1990;27(suppl):S4l-S43.
37. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I: Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995:18:409-413.
38. Luijten JA, Baart de la Faille Kuyp EH: The occurrence of IgM and complement factors along myelin sheaths and peripheral nerves; an imtnu-nohistochcmical study of the Guillain Barré syndrome. Preliminary communication J Neurol Sci 1972:15:219-224.
39. Brechenmacher C, Vital C, Deminiere C, et al: Guillain-Barré syndrome: An ultrastructural study of peripheral nerve in 65 patients. Clin Ncuropathol 1987;6:19-24.
40. Honovar M, Tharakan JK, Hughes RAC, Leibowitz S: A clinicopathological study of the Guillain Barré syndrome. Nine cases and literature review. Brain 1991:114:1245-1269.
41. Gregson NA, Koblar S, Hughes RAC: Antibodies to gangliosides in Guillain-Barré syndrome. Specificity and relationship to clinical features. Q J Med 1993:86:111-117.
42. Van den Berg LG, Marrink J, DeJager AE, Et al: Anti-GM 1 antibodies in patients with the Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1992:58:8-11.
43. Simone IL, Annunziata P, Maimone D, et al: Serum and CSF anti-GM I antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyclinating polyradiculitis. J Neurol Sci 1993:114:49-55.
44. Vriesendorp FJ, Mishu B, Blaser MJ, et al: Serum antibody to GMI. GDIb. peripheral nerve myelin, and Campylobacter jejuni in Guillain-Barré syndrome and controls, correlation and prognosis. Ann Neurol 1993:34:130-135.
45. Roberts MM, Willison H, Vincent A, et al: Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet 1994:343:454-455.
46. Arasaki K, Kusunoki S, Kudo N, et al: Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 1993:16: 587-593.
47. Asbury AK, Aranson BG, Adams RD: The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine Baltimore 1969; 48:173-215.
48. Dahle C, Vrethem M, Erneudh J: T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barré syndrome. J Neuroimmunol 1994:53:219-225.
49. Cornblath DR, Griffin DE, Welch D, Griffin JW, McArthur JC: Quantitative analysis of endoneural T cells in human sural nerve biopsies. J Neuroimmunol 1990:26:113-118.
50. Hughes RAC, Aslan S, Gray LA: Lymphocyte subpopulations and suppressor cell activity in acute polyradiculoneuritis (Guillain-Barré syndrome). Clin Exp Immunol 1983;51 448-454.
51. Hauser SL, Ropper AH, Perlo VP, Reinherz EL, Schlossman SF, Weiner HL: T-cell subsets in human autoimmune disease. Neurology 1982: 32:1320-1321.
52. Atkinson PF, Perry ME, Hall SM, Hughes RAC: Immunoelecromicroscopical demonstration of major histocompatibility class II antigens; expression on endothelial and perivascular cells but not Schwann cells in human neuropathy. Ncuropathol Appl Ncurobiol 1993:19:22-30.
53. Pollard JD, Baverstock J, McLeod JG: Class II antigen expression and inflammatory cells in Guillain-Barré syndrome. Ann Neurol 1987:22: 337-341.
54. Griffin JW, George R, Lobato C, Tylor WR, Yan LC, Glass JD: Macrophage system in peripheral nerves. A review. J Neuropathol Exp Neurol 1993:52:553-560.
55. Hughes RAC, Gray IA, Gregson NA, et al: Immune responses to myelin antigens in Guillain-Barre syndrome. J Neuroimmunol 1984:6:303-312.
56. Khalili-Shirazi A, Hughes RAC, Brostoff SW, et al T cell responses to myelin proteins in Guillain-Barré syndrome. J Neurol Sei 1992: 111:200-203.
57. Taylor WA, Brostoff SW, Hughes RAC: P2 specific lymphocyte transformation in Guillain-Barre and chronic idiopathic dcmyclination polyradiculoneuropathy. J Neurol Sci 1991:104: 52-55.
58. Taylor WA, Hughes RAC: T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1989:24:33-39.
59. Bansil S, Mithen FA, Cook SD, et al: Clinical correlation with serum-soluble interleukin-2 receptor levels in Guillain-Barré syndrome. Neurology 1991;41:1302-1305.
60. Hartung HP, Hughes RAC, Taylor WA, et al: T cell activation in Guillain-Barré syndrome and MS: Elevated serum levels of soluble IL-2 receptors. Neurology 1990;40:215-218.
61. Hartung HP, Toyka KV: T cell and macrophage activation in experimental neuritis and Guillain-Barré syndrome. Ann Neurol 1990: 27(suppl):S57-S63.
62. Hartung HP, Schafer B, Heininger K, et al: The role of interferon gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol 1990:27: 247-257.
63. Yuki N, Sato S, Fujimoto S: et al: Serotype of Campylobacter jejuni, HLA. and the Guillain-Barré syndrome. Muscle Nerve 1992:15:968-969.
64. Yuki N, Sato S, Itoh T, et al: HLA-B35 and acute axonal polyneuropathy following Campylobacter jejuni infection. Neurology 1991:41: 1561-1563.
65. Kuroki S, Saida T, Nukina M, et al: Campylo-bacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta N-acctylglucosa-minc residues. Ann Neurol 1993:33:243-247.
66. Winer JB, Briggs D, Welsh K, et al: HLA antigens in the Guillain-Barre syndrome. 1 Nctt-roimmunol 1988; 18:13-16.
67. Sharief MK, McLean B, Thompson EJ: Elevated serum levels of tumor growth factor alpha in Guillain-Barre syndrome. Ann Neurol 1993:33: 591-596.
68. Said G, Honerbeyrie-Joscowicz M: Nerve lesions induced by macrophage activation. Res Immunol 1992:143:589-599.
69. Hartung HP: Immune mediated dcmycl¡nation. Ann Neurol 1993:33:563-567.
70. Hartung HP, Jung S, Stoll G, et al: Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992:40:197-210.
71. Bansil S, Mithen FA, Singhal BS, et al: Elevated neopterin levels in Guillain-Barre syndrome. Further evidence of immune activation. Arch Neurol 1992:49:1277-1280.
72. Hartung HP, Reiners K, Michels M, et al: Scrum levels of E-selectin (ELAM-1) in immune mediated neuropathies. Neurology 1994:44:1153-1158.
73. Martin S, Rieckmann P, Melchers I, et al: Circulating forms of ICAM-3 (clCAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-l. J Immunol 1995:154: 1951-1955.
74. Koski CL: Characterization of complement fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl):S44-S47.
75. Sawant-Mane S, Estep A, Koski CL: Antibodies of patients with Guillain-Barre syndrome mediate complement dependent cytolysis of rat Schwann cell phenotype. J Neuroimmunol 1994:9:145-152.
76. Koski CL, Sanders ME, Swoveland PT, et al: Activation of terminal components of complement in patients with Guillain-Barrc syndrome and other demyelinating neuropathies. J Clin Invest 1987:80:1492-1497.
77. Sanders ME, Koski CL, Robbins D, et al: Activated temtinal complement in CSF of Guillain-Barre syndrome and multiple sclerosis. J Immunol 1986:136:4454-4459.
78. Lundkvist I, van-Doorn PA, Vermeulen M, Brown A: Spontaneous recovery from the Guillain-Barre syndrome is associated with antiidiopatic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies, Clin Immunol Immunopathol 1993; 67:192-198.
79. Cook SD, Dowling PC, Blumberg BM: Infection and autoimmunity in Guillain-Barre syndrome. Clin Neuroimmunol 1987:17:225-240.
80. Steele JC, Thanasophon S, Gladstone RM, Fleming PC: Mycoplasma pneumoniae as a determinant of the Guillain-Barre syndrome. Lancet 1969:ii:710-714.
81. Hodges GR, Perkins RL: Landry-Guillain-Bar-ré syndrome associated with Mycoplasma pneumoniae infection. JAMA 1969:210:2088-2090.
82. Holt S, Khan MM, Charles RG. Epstein EJ: Polyradiculoneuritis and Mycoplasma pneumoniae infection. Postgrad Med J 1977:53:416-418.
83. Lc Bigot P, Vachon F, Manuel C, Masson M: Neurologic manifestations of Mycoplasma pneumoniae. Apropos of 12 cases. Rev Neurol (Paris) 1976:132:791-798.
84. Murray HW, Masur H, Sentcrfit LB, Roberts RB: The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975:58:229-242.
85. Drücke TB, Pujade-Laurainc E, Poisson M, Zingraff J, Ulmann A, Crosnier J: Measles virus and Guillain-Barrc syndrome during long-term hemodialysis. Am J Med 1976:60:444-446.
86. Parry GJ: Peripheral neuropathies associated with human immunodeficiency virus infection. Ann Neurol 1988;23(suppl):S46-S53.
87. Pachner AR, Steere AC:Thetriadofneurologic manifestations of Lyme disease: Meningitis, cranial neuritis, and radiculoneuritis. Neurology 1985:35:47-53.
88. Center for Disease Control: Guillain-Barré Syndrome Preliminary Surveillance Report. January June 1978. Atlanta. 1978.
89. Melnick SC, Flewett TH: Role of infection in the Guillain-Barré syndrome. J Neurol Neuro-surg Psychiatry 1964;27:395-407.
90. Samantray SK, Johnson SC, Mathai KV, Pulimood BM: Landry-Guillain-Barré-Strohl syndrome. A study of 302 cases. Med J Aust 1977; 2:84-91.
91. Boucharlat J, Groslambert R, Chateau R: Polyradiculoneuritis as a symptom of varicella (a case report). J Med (Lyon) 1968:49:1143-1145.
92. Davies J, Rowlatt RJ: Transient severe hypertension and polyradiculitis after chicken pox. Br Med J 1978;ii: 1608.
93. Welch RG: Chicken-pox and the Guillain-Barré syndrome. Arch Dis Child 1962:37:557-559.
94. Cathala J, Bertrand I, Bolgert M: Paralysie diffuse A type extenso-progressif avec dissociation albumino-cytologiquc et xanthochromie du liquide céphalo-rachidien au cours des oreillons. Mort par asphyxie. Examen anatomique. Bull Mém Soc Hôp (Paris) 1936:52:33-38.
95. Colletts WS, Rabinowitz MA: Mumps polyneuritis: quadriplcgia with bilateral facial paralysis. Arch Intern Med 1928;41:61-65.
96. Linin-Janson G, Strannegard O: Two cases of Guillain-Barré syndrome and encephalitis after measles. BrMedJ 1972;ii:572.
97. Amason BGW: Inflammatory polyradiculopathies; in Dyck PJ. Thomas PK. Lambert EH. (eds): Peripheral Neuropathy. Philadelphia. Saunders. 1975, pp. 1110-1148.
98. Phillips PE: Guillain-Barré syndrome after measles. B Med J 1972:4:50.
99. Saeed A A, Lange LS: Guillain-Barre syndrome after rubella. Postgrad Med J 1978:54:333-334.
100. Bertrand A, Janbon F, Clot J, Milanc J, Bose E: Guillain-Barrc polyradiculoneuritis and influenza virus. Presse Med 1971:79:2328.
101. Novak M: Guillain-Barré syndrome as a sequela of influenza. Ccsk Neurol Neurochir 1975:38:314-316.
102. Nowicki J: Neurological syndromes occurring in the course of influenza. Neurol Neurochir Pol 1973:7:695-699.
103. Wells CEC: Neurological complications of so-called influenza.' A winter study in South-East Wales. Br Med J 1971; 1:369-373.
104. Nelson DB, Hurwitz ES, Sullivan-Bolyai JZ, Morens DM. Schonberger LB: Reye’s syndrome in the United States in 1977 1978. a non-infiuenza-B virus year. J Infect Dis 1979; 140:436-439.
105. Partnow MJ, Devereaux MW, Humphries RI: Infectious hepatitis and the Guillain-Barré syndrome. J Med Soc N J 1980:77:118-120.
106. Plough IC, Ayerle RS: The Guillain-Barré syndrome associated with acute hepatitis. N Engl J Med 1953:249:61-62.
107. Rimbauld L, Janbon M, Bertrand L: Polyrad-iculoncvritc aiguë mortelle contemporaine d'une hépatite infectieuse. Bull Soc Méd Hôp (Paris) 1960:76:912-920.
108. Mushinski JF, Taniguchi RM, Stiefel JW: Guillain-Barré syndrome associated with ulcer-oglandular tularemia. Neurology 1964:14: 877-879.
109. Lopez de Munain A, Espinal-Valencia JB, Marti-Masso JF, Perez-Trallero E, Garcia-Arenzona JM: Antibodies to Borrelia burgdorferi in Guillain-Barré syndrome. Lancet 1990:335:1168.
110. Kaldor J, Speed RB: Guillain-Barré Syndrome and Campylobacter jejuni: A serological study. BrMedJ 1984:228:1867-1870.
111. Gruencwald R, Ropper AH, Lior H, Chan J, Lee R, Molinaro VS: Serologic evidence of Campylobacter jejuni/coW enteritis in patients with Guillain-Barré Syndrome. Arch Neurol 1991:48:1080-1082.
112. Stratton KR, Howe CJ, Johnston RB: Adverse Events Associated with Childhood Vaccines. Washington. National Academic Press. 1994.
113. Rocclli JD, Bass JW, Pang L: Guillain-Barré syndrome and influenza vaccination in the US army. J Epidemiol 1991:133:952-955.
114. Safranek TJ, Lawrence DN, Kurland LT, et al: Reassessment of the association between the Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977; results of a two state study; Expert Neurology Group. Am J Epidemiol 1991.133:940-951.
115. Hamachudha T, Griffin DE, Chen WW, et al: Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology 1988:38:375-378.
116. Kinnunen E, Farkkila M, Hovi T. et al: Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign Neurology 1989;39:1034-1136.
117. Yuki N, Taki T, Inagaki F. et al: A bacterium Iipopoly.saccharide that elicits Guillain-Barré syndrome lias a GM1 ganglioside-like structure. J Exp Med 1993:178:1771-1775.
118. Feasby TE, Hahn AF, Gilbert JJ: Passive transfer studies in Guillain-Barre polyneuropathy. Neurology 1982:32:1159-1167.
119. Saida T, Saida K, Lisak RP, Brown MJ, Silber-berg DH, Asbury AK: In vivo demyclinating activity of sera from patients with Guillain-Barre syndrome. Ann Neurol 1982; 11:69-75.
120. Harrison BM, Hansen LA, Pollard JD, McLeod JG: Dcmyclination induced by serum from patients with Guillain-Barre syndrome. Ann Neurol 1984:15:163-170.
121. Sumner AJ, Lisak RP, Brown MJ, Ashbury AK: Demyclinating activity of Guillain-Barre syndrome (GBS) serum (abstract). Neurology 1983:33:81.
122. Low PA, Schmelzer JD, Dyck PJ: Results of endoneural injection of Guillain-Barre scrum in Lewis rats. Mayo Clin Proe 1982:57:360-364.
123. Sawanl-Manc S, Clark MB, Koski CL: In vitro demyelination by scrum antibody from patients with Guillain-Barre syndrome requires terminal complement complexes. Ann Neurol 1991;29:397-404.
124. Oomes PG, van der Meche FGA, Markus Silvis L, et al: In vivo effects of sera from Guillain Barre subgroups: and electrophysiological and histological study on rat nerves. Muscle Nerv e 1991:14:1013-1020.
125. Hahn AF, Feasby TE, Wilkie L, et al: Antiglactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve 1993:16:1174-1180.
126. Waksman BH, Adams RD: Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvant. J Exp Med 1955; 102:213-235.
127. Archclos JJ, Roggenbruck K, Schneider-Schaulies J, et al: Detection and quantification of antibodies to the extracellular domain of P0 during experimental allergic neuritis. J Neurol Sci 1993;117:197-205.
128. Hahn AF, Feasby TE, Guilbert JJ: Blood nerve barrier studies in experimental neuritis. Acta Neropathol Bcrl 1985:68:101-109.
129. Povvel HC, Brahcny SL, Myers RR, et al: Early changes in experimental allergic neuritis. Lab Invest 1983;48:332-338.
130. Hartung HP, Stoll G, Toyka KV: Immune reaction in the peripheral nervous system, in Dyck PJ. Thomas PK. Griffin JW. Low PA. Poduslo JF (eds): Peripheral Neuropathy. Philadelphia. Saunders, 1993, vol 3. pp 418-444.
131. Archclos JJ, Maurer M, Jung S: Inhibition of experimental allergic neuritis by an antibody to lymphocyte associated antigen-1. Lab Invest 1994:70:667-675.
132. Spies JM, Pollard JD, Bonner JG: Synergy between antibody and P2-rcactive T-cclls in experimental allergic neuritis. J Neuroimmunol 1995:57:77-84.
133. Hartung HP, Pollard JD, Harvey GK, et al: Im-munopathogcncsis of the Guillain-Barre syndrome. Muscle Nerve 1995:18:137-153.
134. Stoll G, Hartung HP: The role of macrophages in degeneration and immune mediated demyelination in the peripheral immune system. Adv Neuroimmunol 1992:2:163-179.
135. Schmidt BA, Stoll G, Hartung HP, et al: Macrophages but not Schwann cells express la antigen in experimental allergic neuritis. Ann Neurol 1990:28:70-77.
136. Hartung HP, Schafer B, van der Meide PH. et al: The role of interferon gamma in the pathogenesis of experimental autoimmune disease of the peripheral nerv ous system. Ann Neurol 1990:27:247-257.
137. Schmidt B, Stoll G, van der Meide P, et al: Transient cellular expression of gamma interferon in myelin induced and T-cell line mediated experimental autoimmune neuritis. Brain 1992:115:1633-1646.
138. Baron P, Constantin G, D'Andrea A. et al: Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 protein. Proc Nall Acad Sci USA 1993.90: 4414-4418.
139. Stoll G, Jung S, Jander S, et al: Tumor necrosis factor alpha in immune mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993:45:175-182.
140. Kiefer R, Gold R, Gehrmann J. et al: Transforming growth factor beta expression in reactive spinal cord microglia and meningeal inflammatory cells during experimental allergic neuritis. J Ncurosci Res 1993;36:391-398.
141. Zhu J, Mix E, Olsson T, et al: Cellular mRNA expression of interferon gamma, IL-4 and transforming growth factor beta by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin Exp Immunol 1994:98:306-312.
142. Zuh J, Link II. Mix E, et al: The like cell responses to peripheral nerve myelin component over the course experimental allergic neuritis in Lewis rats. Acta Neurol Scand 1994:90: 19-25.
143. The Guillain-Barre Syndrome Study Group: Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985:35:1096-1104.
144. Hughes RAC: Ineffectiveness ofhigh-do.se intravenous mcthylprcdnisolonc in Guillain-Barre syndrome. Lancet 1991:338:1142.
145. Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, Safvvenberg, J: Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984:ii: 1296-1298.
146. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome: Efficiency of plasma exchange in Guillain-Barre syndrome: Role of replacement fluids. Ann Neurol 1987;22:753-761.
147. van der Mceh FGA, Schmitz PIM. The Dutch Guillain-Barre Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992:326:1123-1129.
148. Jayne DRW, Esnault VLM, Lockwood CM: ANC'A anti-idiotype antibodies and the treatment of systemic vasculitis and intravenous immunoglobulin. J Autoimmun 1993:6:207-219.
149. Shocnfeld Y, Isenberg DA: High dose intravenous immunoglobulins, in The Mosaic of Autoimmunity. Amsterdam. Elsevier. 1988. pp 462-465.
150. Korn-Lubetzki I, Abramsky O: Acute and chronic demyclinating inflammatory polyradiculopathy: Association with autoimmune diseases and lymphocyte response to human neu-ritogenic protein. Arch Neurol 1986:43:604-608
151. Jung S, Schlucsener HJ, Schmidt B: Therapeutic effect of transforming growth factor beta 2 on actively induced EAN but not adoptive transfer EAN. Immunology 1994:83:545-551.